1. Academic Validation
  2. ALZ-801 prevents amyloid β-protein assembly and reduces cytotoxicity: A preclinical experimental study

ALZ-801 prevents amyloid β-protein assembly and reduces cytotoxicity: A preclinical experimental study

  • FASEB J. 2025 Feb 15;39(3):e70382. doi: 10.1096/fj.202402622R.
Daiki Muramatsu 1 Takahiro Watanabe-Nakayama 2 Mayumi Tsuji 3 Kenichi Umeda 2 Sadao Hikishima 1 Hiroto Nakano 1 Yasuhiro Sakashita 1 Tokuhei Ikeda 1 Hiroki Konno 2 Noriyuki Kodera 2 Toshio Ando 2 Moeko Noguchi-Shinohara 1 Kenjiro Ono 1
Affiliations

Affiliations

  • 1 Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • 2 World Premier International Research Center Initiative (WPI)-Nano Life Science Institute, Kanazawa University, Kanazawa, Japan.
  • 3 Pharmacological Research Center, Showa University, Tokyo, Japan.
Abstract

Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disorder, mainly characterized by amyloid β (Aβ) accumulation in the brain. Numerous new agents are currently undergoing clinical trials as disease-modifying therapies (DMTs) targeting Aβ. ALZ-801 is a promising candidate DMT for AD, with a phase 3 trial of ALZ-801 ongoing specifically for Apolipoprotein E (apoE) ε4 homozygous patients with early-stage AD. This study aimed to examine the effects of ALZ-801 on Aβ assembly and explore its toxicological profile. Thioflavin T (ThT) assays and two imaging modalities-transmission electron microscopy (TEM) and high-speed atomic force microscopy (HS-AFM)-were used to evaluate ALZ-801's effects on Aβ assembly. To assess the effect of ALZ-801 on Aβ42-induced cytotoxicity, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and Lactate Dehydrogenase (LDH) assays were performed. ThT assays revealed increased lag time and decreased fluorescence in the presence of ALZ-801, confirming inhibition of Aβ42 fibril formation, as confirmed by TEM. Real-time observation using HS-AFM revealed that ALZ-801 inhibited the formation of Aβ42 fibril from low-molecular-weight (LMW)-Aβ42 in the presence of Aβ42 seeds. HS-AFM also revealed that globular aggregates from LMW-Aβ42 were significantly larger with ALZ-801, with few fibrils noted. MTT and LDH assays indicated that ALZ-801 prevented LMW-Aβ42-induced cytotoxicity but did not reduce cytotoxicity induced by high-molecular-weight-Aβ42. ALZ-801 can inhibit Aβ42 aggregation by preventing both nucleus formation and fibril elongation, while promoting large globular oligomer formation, and can significantly reduce LMW-Aβ42-induced cytotoxicity. These findings underscore the potential of ALZ-801 as an effective DMT for apoE ε4 homozygous patients with AD.

Keywords

ALZ‐801; Alzheimer disease; amyloid beta‐peptides; apolipoproteins E; atomic force, microscopy; protein aggregates.

Figures
Products